SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy
- PMID: 35877834
- DOI: 10.1161/CIRCULATIONAHA.122.060348
SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy
Keywords: Editorials; clinical trials; diabetes; heart failure; mortality; sodium glucose co-transporter 2 inhibitors.
Comment on
-
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.Circulation. 2022 Jul 26;146(4):279-288. doi: 10.1161/CIRCULATIONAHA.122.059725. Epub 2022 Apr 4. Circulation. 2022. PMID: 35377706 Free PMC article. Clinical Trial.
-
Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).Circulation. 2022 Jul 26;146(4):289-298. doi: 10.1161/CIRCULATIONAHA.122.059038. Epub 2022 Jun 29. Circulation. 2022. PMID: 35766022 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
